Theravance, Astellas get telavancin approvable letter

THRX and Astellas (Tokyo:4503) received an approvable letter from FDA for an NDA for telavancin to treat complicated skin and skin structure infections (cSSSIs) caused by Gram-positive bacteria, inclu...